{"id":61680,"date":"2025-08-04T10:06:37","date_gmt":"2025-08-04T08:06:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/"},"modified":"2025-08-04T10:06:37","modified_gmt":"2025-08-04T08:06:37","slug":"nucleus-network-acquires-hammersmith-medicines-research","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/","title":{"rendered":"Nucleus Network Acquires Hammersmith Medicines Research"},"content":{"rendered":"
\n

\nEstablishes First Truly Global Early-Phase Clinical Trial Network<\/b><\/p>\n

BRISBANE, Australia & LONDON–(BUSINESS WIRE)–Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom\u2019s most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network\u2019s global growth, establishing the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe acquisition brings together two organisations with a shared mission: advancing medicine and improving lives. It also honours the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe. With complementary scientific expertise and a strong, mutual commitment to participant safety and ethical conduct, the combined organisation is well positioned to accelerate clinical development and deliver inclusive, high-quality studies across three continents.<\/p>\n

\n\u201cWe are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR\u2019s legacy,\u201d said <\/i>Teena Pisarev, Chief Executive Officer of Nucleus Network. \u201cThis acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.\u201d<\/i><\/p>\n

\nA New Standard for Early-Phase Clinical Trials<\/b><\/p>\n

\nWith the acquisition of HMR, Nucleus Network is setting a new global benchmark in the delivery of early-phase clinical trials. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. By harnessing the strength of our globally leading and multi-jurisdictional business development team, we will work in close partnership with sponsors to guide trials to the geographic locations that best align with their strategic priorities. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk.<\/p>\n

\nThe expanded geographic footprint expands access to broader and more diverse volunteer and patient populations. This scale supports faster recruitment and more inclusive study designs, both of which are critical for first-in-human and adaptive trial protocols. HMR\u2019s decades of scientific and operational excellence complement Nucleus Network\u2019s advanced infrastructure and digital capabilities. Together, they bring added precision to study execution and data quality, driving robust outcomes across all sites.<\/p>\n

\nSponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution. This integration further strengthens Nucleus Network\u2019s position as the most experienced global provider dedicated to early-phase clinical research.<\/p>\n

\nAt the same time, Nucleus Network will continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies.<\/p>\n

\n\u201cThis acquisition expands what\u2019s possible for our sponsors<\/i>,\u201d Pisarev added. \u201cIt deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world.\u201d<\/i><\/p>\n

\nNucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from ~2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships.<\/p>\n

\nAbout Nucleus Network<\/b><\/p>\n

\nNucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States, and the United Kingdom. With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation.<\/p>\n

\nFor more information, visit: www.nucleusnetwork.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/p>\n

\nDani Stoltzfus
\n
Mighty Spark Communications
\n
Email: dstoltzfus@mightysparkcommunications.com<\/a><\/p>\n

\nKatrina Campbell
\n
EVP Marketing & Communications
\n
Nucleus Network
\n
Email: k.campbell@nucleusnetwork.com.au<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Establishes First Truly Global Early-Phase Clinical Trial Network BRISBANE, Australia & LONDON–(BUSINESS WIRE)–Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom\u2019s most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network\u2019s global growth, establishing … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61680","6":"format-standard","7":"category-industry"},"yoast_head":"\nNucleus Network Acquires Hammersmith Medicines Research - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nucleus Network Acquires Hammersmith Medicines Research - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Establishes First Truly Global Early-Phase Clinical Trial Network BRISBANE, Australia & LONDON–(BUSINESS WIRE)–Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom\u2019s most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network\u2019s global growth, establishing ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-04T08:06:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250804665702\/en\/2542246\/22\/Nucleus_Network_Master_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nucleus Network Acquires Hammersmith Medicines Research\",\"datePublished\":\"2025-08-04T08:06:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/\"},\"wordCount\":615,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804665702\\\/en\\\/2542246\\\/22\\\/Nucleus_Network_Master_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/\",\"name\":\"Nucleus Network Acquires Hammersmith Medicines Research - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804665702\\\/en\\\/2542246\\\/22\\\/Nucleus_Network_Master_Logo_RGB.jpg\",\"datePublished\":\"2025-08-04T08:06:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804665702\\\/en\\\/2542246\\\/22\\\/Nucleus_Network_Master_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804665702\\\/en\\\/2542246\\\/22\\\/Nucleus_Network_Master_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleus-network-acquires-hammersmith-medicines-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nucleus Network Acquires Hammersmith Medicines Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nucleus Network Acquires Hammersmith Medicines Research - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/","og_locale":"en_US","og_type":"article","og_title":"Nucleus Network Acquires Hammersmith Medicines Research - Pharma Trend","og_description":"Establishes First Truly Global Early-Phase Clinical Trial Network BRISBANE, Australia & LONDON–(BUSINESS WIRE)–Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom\u2019s most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network\u2019s global growth, establishing ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-04T08:06:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250804665702\/en\/2542246\/22\/Nucleus_Network_Master_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nucleus Network Acquires Hammersmith Medicines Research","datePublished":"2025-08-04T08:06:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/"},"wordCount":615,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250804665702\/en\/2542246\/22\/Nucleus_Network_Master_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/","url":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/","name":"Nucleus Network Acquires Hammersmith Medicines Research - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250804665702\/en\/2542246\/22\/Nucleus_Network_Master_Logo_RGB.jpg","datePublished":"2025-08-04T08:06:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250804665702\/en\/2542246\/22\/Nucleus_Network_Master_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250804665702\/en\/2542246\/22\/Nucleus_Network_Master_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nucleus-network-acquires-hammersmith-medicines-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nucleus Network Acquires Hammersmith Medicines Research"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61680"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61680\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}